Results 41 to 50 of about 180,701 (284)

Neutralizing antibodies for SARS-CoV-2 infection

Revista Española de Quimioterapia, 2022
The COVID-19 pandemic has boosted significant research in developing monoclonal antibodies (mAbs) to treat and prevent SARS-CoV-2 infection. Clinical trials have shown that mAbs are safe and effective in preventing hospitalization and death in patients with mild to moderate COVID-19 risk factors for progression.
openaire   +2 more sources

SARS-CoV-2 and Anti-Cardiolipin Antibodies

Clinical Medicine Insights: Case Reports, 2020
The current COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to distinct diagnostic and management challenges for front-line healthcare workers. The risk of excessive coagulation activation leading to a cascade of thrombotic events in critically ill patients with SARS-CoV-2 is now well reported.
Mazen Jizzini, Mohsin Shah, Kehua Zhou
openaire   +4 more sources

Saliva SARS-CoV-2 Antibody Prevalence in Children

Microbiology Spectrum, 2021
Comprehending humoral immunity to SARS-CoV-2, including in children, is crucial for future public health and vaccine strategies. Others have suggested that mucosal antibody measurement could be an important and more convenient tool to evaluate humoral immunity compared to circulating antibodies.
Maya W. Keuning, Marloes Grobben, Anne-Elise C. de Groen, Eveline P. Berman-de Jong, Merijn W. Bijlsma, Sophie Cohen, Mariet Felderhof, Femke de Groof, Daniel Molanus, Nadia Oeij, Maarten Rijpert, Hetty W. M. van Eijk, Gerrit Koen, Karlijn van der Straten, Melissa Oomen, Remco Visser, Federica Linty, Maurice Steenhuis, Gestur Vidarsson, Theo Rispens, Frans B. Plötz, Marit J. van Gils, Dasja Pajkrt   +22 more
openaire   +3 more sources

Equine Hyperimmune Serum against the Inactivated SARS-CoV-2 Has Antibodies Neutralizing Titers [PDF]

Brazilian Archives of Biology and Technology
The use of passive immunization could be a strategy for the control of SARS-CoV-2 infections. Our study proposes to produce anti-SARS-CoV-2 antibodies from the immunization of horses, and purify F(ab’)2 fragment aiming to provide a therapy capable of ...
Neida Lucia Conrad, Vitória Sequeira Gonçalves Zorzi, Francisco Denis Souza Santos, César Graner, Marcelle Moura Silveira, Juliana Schons Gularte, Micheli Filippi, Karoline Schallenberger, Juliane Deise Fleck, Bruno Lopes Abbadi, Cristiano Valim Bizarro, Pablo Machado, Luiz Augusto Basso, Fabrício Rochedo Conceição, Carlos Eduardo Wayne Nogueira, Fernando Rosado Spilki, Fábio Pereira Leivas Leite   +16 more
doaj   +1 more source

SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responsesResearch in context

EBioMedicine, 2023
Summary: Background: Mucosal antibodies play a key role in the protection against SARS-CoV-2 infection in the upper respiratory tract, and potentially in limiting virus replication and therefore onward transmission. While systemic immunity to SARS-CoV-2
Olha Puhach, Mathilde Bellon, Kenneth Adea, Meriem Bekliz, Krisztina Hosszu-Fellous, Pascale Sattonnet, Nicolas Hulo, Laurent Kaiser, Isabella Eckerle, Benjamin Meyer   +9 more
doaj   +1 more source

Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19. [PDF]

, 2020
BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel beta-coronavirus that has recently emerged as the cause of the 2019 coronavirus pandemic (COVID-19).
Fitzgerald, Robert L, Hoffman, Melissa A, Kelner, Michael J, McLawhon, Ronald W, Reed, Sharon L, Suhandynata, Raymond T   +5 more
core  

Infectivity-enhancing antibodies against SARS-CoV-2

Uirusu, 2021
Antibodies against the receptor binding domain of the spike protein of SARS-CoV-2 play an important role in preventing infection as neutralizing antibodies. However, antibodies that recognize a specific site on the N-terminal domain of the spike protein induce an open domain of receptor binding that increases the binding of ACE2 and enhances the ...
openaire   +2 more sources

Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors

Clinical & Translational Immunology, 2021
Objectives Characterisation of the human antibody response to SARS‐CoV‐2 infection is vital for serosurveillance purposes and for treatment options such as transfusion with convalescent plasma or immunoglobulin products derived from convalescent plasma ...
Maurice Steenhuis, Gerard vanMierlo, Ninotska IL Derksen, Pleuni Ooijevaar‐de Heer, Simone Kruithof, Floris L Loeff, Lea C Berkhout, Federica Linty, Chantal Reusken, Johan Reimerink, Boris Hogema, Hans Zaaijer, Leo van deWatering, Francis Swaneveld, Marit J vanGils, Berend Jan Bosch, S Marieke vanHam, Anja tenBrinke, Gestur Vidarsson, Ellen C van derSchoot, Theo Rispens   +20 more
doaj   +1 more source

Molecular aspects of MERS-CoV [PDF]

, 2017
This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Al-Ahmed, Shamsah H., Al-Tawfiq, Jaffar A., Bazzi, Ali M., Rabaan, Ali A.   +3 more
core   +1 more source

Nebulized mRNA‐Encoded Antibodies Protect Hamsters from SARS‐CoV‐2 Infection

Advanced Science, 2022
Despite the success of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccines, there remains a clear need for new classes of preventatives for respiratory viral infections due to vaccine hesitancy, lack of sterilizing immunity, and for at ...
Daryll Vanover, Chiara Zurla, Hannah E. Peck, Nichole Orr‐Burks, Jae Yeon Joo, Jackelyn Murray, Nathan Holladay, Ryan A. Hobbs, Younghun Jung, Lorena C. S. Chaves, Laura Rotolo, Aaron W. Lifland, Alicia K. Olivier, Dapeng Li, Kevin O. Saunders, Gregory D. Sempowski, James E. Crowe Jr., Barton F. Haynes, Eric R. Lafontaine, Robert J. Hogan, Philip J. Santangelo   +20 more
doaj   +1 more source